Amphastar expands board, adds Anthony Pierce as director

On July 9, 2026, Amphastar Pharmaceuticals' board of directors acted on a recommendation from its Nominating and Corporate Governance Committee to increase the number of authorized board seats from ten to eleven and name Anthony Pierce a Class III director, with his term running until the company's 2028 annual meeting of stockholders, effective immediately.¹ The company noted that Pierce was not appointed to serve on any committees of the Board at this time.¹

The board concluded that Pierce has no relationship that would interfere with his independent judgment as a director and that he qualifies as independent under Nasdaq's listing standards.¹ The filing also states that there are no arrangements or understandings tying his selection to any other party, and no transactions between Pierce and the company that would require reporting under Item 404(a) of Regulation S-K.¹

On compensation, Amphastar said Pierce will receive both cash and equity pay, including an annual cash retainer of $55,000, prorated for his start date.¹ His equity award will be split evenly between restricted stock units and stock options, carrying a combined grant-date value of $300,000 and vesting after one year of continued service, under terms consistent with the company's other non-employee directors as outlined in its April 13, 2026 proxy statement, per the company's disclosure.¹

Amphastar also said it will sign its standard indemnification agreement with Pierce in connection with his appointment.¹ The 8-K was signed by Chief Financial Officer William J. Peters and dated July 13, 2026.